Address
Building III
Langhorne, TX 78746
United States of America (the)
Phone
512 614 1848
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Matthew Pauls | Chairman & Chief Executive Officer | 975,000 | 1971 |
| David L. Lowrance | Chief Financial & Administrative Officer and Secretary | 665,625 | 1968 |
| Robert Lutz | Chief Operating Officer | 665,625 | 1969 |
| Yasmine Wasfi | Chief Medical Officer | 681,578 | N/A |
| Brian Robinson | Executive Vice President of Global Medical Affairs | 0 | N/A |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | 0 | N/A |
| Anne Erickson | Chief Business & Corporate Affairs Officer | 0 | 1972 |
| Kate McCabe | Chief Legal Officer | 0 | 1986 |
| Brian Maurer | Head of Clinical Operations | 0 | N/A |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations | 0 | N/A |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.